| Literature DB >> 26708164 |
Eleonora Brognara1, Enrica Fabbri1, Giulia Montagner1, Jessica Gasparello1, Alex Manicardi2, Roberto Corradini2, Nicoletta Bianchi1, Alessia Finotti1, Giulia Breveglieri1, Monica Borgatti1, Ilaria Lampronti1, Roberta Milani1, Maria Cristina Dechecchi3, Giulio Cabrini3, Roberto Gambari1.
Abstract
The biological activity of a combined treatment of U251, U373 and T98G glioma cell lines with two anti-miR PNAs, directed against miR‑221 and miR‑222 and conjugated with an ocataarginine tail (R8-PNA-a221 and R8-PNA-a222) for efficient cellular delivery, was determined. Apoptosis was analyzed, and the effect of the combined treatment of glioma cells with either or both PNAs on the reversion of drug-resistance phenotype was assessed in the temozolomide-resistant T98G glioma cell line. Selectivity of PNA/miRNA interactions was studied by surface plasmon resonance (SPR)-based Biacore analysis. Specificity of the PNA effects at the cellular level was analyzed by RT-qPCR. These experiments support the concept that the effects of R8-PNA-a221 and R8-PNA-a222 are specific. The studies on apoptosis confirmed that the R8-PNA-a221 induces apoptosis and demonstrated the pro-apoptotic effects of R8-PNA-a222. Remarkably, increased pro-apoptotic effects were obtained with the co-administration of both anti-miR‑221 and anti-miR‑222 PNAs. In addition, co-administration of R8-PNA-a221 and R8-PNA-a222 induced apoptosis of TMZ-treated T98G cells at a level higher than that obtained following singular administration of R8-PNA-a221 or R8-PNA-a222.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26708164 DOI: 10.3892/ijo.2015.3308
Source DB: PubMed Journal: Int J Oncol ISSN: 1019-6439 Impact factor: 5.650